COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0G5XV
|
|||
Drug Name |
Zanubrutinib
|
|||
Synonyms |
UNII-AG9MHG098Z; AG9MHG098Z; BGB3111; Brukinsa; Brukinsa (TN); Zanubrutinib [INN]; Zanubrutinib [USAN]; Zanubrutinib [USAN:INN]; Zanubrutinib (USAN/INN); D11422; BGB-3111; BGB 311
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C27H29N5O3
|
|||
Canonical SMILES |
C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
|
|||
InChI |
1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
|
|||
InChIKey |
RNOAOAWBMHREKO-QFIPXVFZSA-N
|
|||
CAS Number |
CAS 1691249-45-2
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
1 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.